CD22 (Clusters of Differentiation 22) inhibitors
- Name
- CD22 (Clusters of Differentiation 22) inhibitors
- Accession Number
- DBCAT005742
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox A CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment. - Drugs & Drug Targets
Drug Target Type Inotuzumab ozogamicin P-glycoprotein 1 transporter Inotuzumab ozogamicin B-cell receptor CD22 target Moxetumomab pasudotox B-cell receptor CD22 target Moxetumomab pasudotox Elongation factor 2 target